13F Holdings
中文EN

FEMY FEMASYS INC

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1339005 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-4.2%
TTM net income YoY38.7%
TTM EPS YoY175.8%
Revenue 3-yr CAGR21.8%
Net income 3-yr CAGR—

Margins

Gross margin59.9%
Operating margin-929.9%
Net margin-614.7%
FCF margin-877.5%
EBITDA margin-913.3%

Returns

ROE-76.9%
ROA-47.3%
ROIC (approx.)-935.4%
Asset turnover0.08x

Leverage & solvency

Liabilities / assets23.0%
Debt / equity0.00x
Current ratio8.67x
Interest coverage-18.91x

Cash quality & payout

Operating cash flow / net income1.41x
Accruals ratio19.2%
Payout ratio—
Capex / revenue12.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$2.29M$1.63M$1.07M$1.21M$1.18M
Cost of revenue$872,400$544,903$380,069$441,938$370,384
Gross profit$1.42M$1.08M$691,901$764,280$809,305
R&D expense$7.58M$8.22M$7.21M$5.81M$4.08M
SG&A expense$6.65M$6.33M$6.86M$5.43M$4.26M
Operating income-$17.59M-$17.79M-$14.51M-$11.60M-$8.34M
Interest expense$1.89M$1.60M$165,390$13,464$19,226
Pretax income-$18.63M-$18.81M-$14.24M-$11.39M-$7.53M
Income tax$1,297$9,602$4,338$6,300$4,000
Net income-$18.63M-$18.82M-$14.25M-$11.39M-$7.54M
EBITDA-$17.25M-$17.49M-$14.02M-$11.04M-$7.75M
EPS (basic)-0.47-0.85-0.93-0.96-1.12
EPS (diluted)-0.47-0.85-0.93-0.96-1.12
Weighted avg. shares (diluted)39.55M22.27M15.38M11.82M6.71M
Balance sheet
Cash & equivalents$9.27M$3.45M$21.72M$12.96M$24.78M
Receivables$616,600$488,373$98,906$77,470$84,258
Inventory$5.74M$3.05M$667,118$436,723$208,270
Current assets$16.46M$8.02M$23.18M$14.13M$25.63M
PP&E, net$1.90M$1.60M$1.11M$1.48M$1.60M
Intangibles$134,914$65,918$0$3,294$25,093
Total assets$20.72M$12.45M$27.76M$16.90M$28.58M
Current liabilities$3.64M$8.58M$3.05M$1.53M$1.69M
Total liabilities$14.85M$10.14M$9.40M$1.65M$2.24M
Shareholders' equity$5.87M$2.30M$18.35M$15.24M$26.33M
Shares outstanding2.98M23.36M21.66M11.87M11.80M
Cash flow statement
Operating cash flow-$18.69M-$19.44M-$11.28M-$10.73M-$7.93M
Capital expenditure$525,007$761,706$143,917$407,475$306,868
Free cash flow-$19.22M-$20.21M-$11.42M-$11.14M-$8.24M
Investing cash flow-$630,098-$847,764-$143,917-$407,475-$306,868
Financing cash flow$25.14M$2.03M$20.18M-$681,645$29.70M
Depreciation & amortization$342,034$297,318$483,481$561,233$591,068
Stock-based compensation$790,145$444,147$675,700$224,939$193,366
Share buybacks—$60,753$229,953$0—

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.